Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel

被引:34
作者
Nishio, Ryo [1 ]
Shinke, Toshiro [1 ]
Otake, Hiromasa [1 ]
Sawada, Takahiro [1 ]
Haraguchi, Yoko [1 ]
Shinohara, Masakazu [1 ]
Toh, Ryuji [1 ]
Ishida, Tatsuro [1 ]
Nakagawa, Masayuki [1 ]
Nagoshi, Ryoji [1 ]
Kozuki, Amane [1 ]
Inoue, Takumi [1 ]
Hariki, Hirotoshi [1 ]
Osue, Tsuyoshi [1 ]
Taniguchi, Yu [1 ]
Iwasaki, Masamichi [1 ]
Hiranuma, Noritoshi [1 ]
Konishi, Akihide [1 ]
Kinutani, Hiroto [1 ]
Shite, Junya [1 ]
Hirata, Ken-ichi [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Div Cardiovasc Med, Dept Internal Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
CYP2C19; Intra-stent thrombi; Major adverse cardiac events; Optical coherence tomography; Target lesion revascularization; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; 6-MONTH FOLLOW-UP; PLATELET REACTIVITY; TASK-FORCE; SIROLIMUS; CYP2C19; THROMBOSIS; CYP2C19-ASTERISK-2;
D O I
10.1253/circj.CJ-12-0476
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cytochrome P450 (CYP) 2C19 polymorphism is associated with reduced responsiveness to clopidogrel and poor clinical outcome after drug-eluting stent (DES) implantation, but its contribution to lesion outcome after DES implantation is unclear. Methods and Results: The study included 160 Japanese patients who received clopidogrel and underwent DES implantation with follow-up angiography. Patients were divided into 3 groups by CYP2C19 polymorphism: extensive metabolizers (EM), intermediate metabolizers (IM), and poor metabolizers (PM). The incidence of major adverse cardiac events (MACE) and target lesion revascularization (TLR) were compared among the 3 groups. Optical coherence tomography (OCT) was performed for 120 patients to evaluate the incidence of intra-stent thrombi. Of the 160 patients, the proportion of EM, IM, and PM was 37.5%, 48.1%, and 14.4%, respectively. The incidence of TLR and MACE was more frequent in IM and PM than EM (TLR: 18.2% and 26.1% vs. 3.3%, P=0.008, MACE: 22.1% and 30.4% vs. 5.0%, P=0.005). Among the 120 patients who underwent follow-up OCT, intra-stent thrombi were more frequently detected in IM and PM than in EM (45.6% and 63.2% vs. 20.5%, P=0.005). The incidence of TLR was significantly higher in patients with than in those without intra-stent thrombi (27.7% vs. 6.8%, P=0.003). Conclusions: CYP2C19 loss-of-function polymorphism might be associated with the incidence of MACE and TLR in association with intra-stent thrombi. (Circ J 2012; 76: 2348-2355)
引用
收藏
页码:2348 / 2355
页数:8
相关论文
共 50 条
[21]   Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention [J].
Sibbing, Dirk ;
Stegherr, Julia ;
Latz, Wolfgang ;
Koch, Werner ;
Mehilli, Julinda ;
Doerrler, Katharina ;
Morath, Tanja ;
Schoemig, Albert ;
Kastrati, Adnan ;
von Beckerath, Nicolas .
EUROPEAN HEART JOURNAL, 2009, 30 (08) :916-922
[22]   Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped? [J].
Kassimis, George ;
Stavrou, Eleana F. ;
Alexopoulos, Dimitrios ;
Athanassiadou, Aglaia .
CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (13) :2489-2495
[23]   Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease [J].
Chen, Mao ;
Liu, Xiao-Jing ;
Yan, Shao-Di ;
Peng, Yong ;
Chai, Hua ;
Li, Qiao ;
Wei, Jia-Fu ;
Xu, Yuan-Ning ;
Huang, De-Jia .
ATHEROSCLEROSIS, 2012, 220 (01) :168-171
[24]   Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis [J].
Hou, Xiaowen ;
Shi, Jingpu ;
Sun, Hao .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (09) :1041-1047
[25]   Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease [J].
Tresukosol, Damrus ;
Suktitipat, Bhoom ;
Hunnangkul, Saowalak ;
Kamkaew, Ruttakarn ;
Poldee, Saiphon ;
Tassaneetrithep, Boonrat ;
Likidlilid, Atip .
PLOS ONE, 2014, 9 (10)
[26]   Cytochrome P450 2C19 Polymorphism, Suboptimal Reperfusion and All-Cause Mortality in Patients with Acute Myocardial Infarction [J].
Malek, Lukasz A. ;
Przyluski, Jakub ;
Spiewak, Mateusz ;
Klopotowski, Mariusz ;
Kostrzewa, Grazyna ;
Kruk, Mariusz ;
Ploski, Rafal ;
Witkowski, Adam ;
Ruzyllo, Witold .
CARDIOLOGY, 2010, 117 (02) :81-87
[27]   Serum interleukin-18 levels as a predictor for patients with genetic dysfunction of cytochrome P450 2C19 in dual antiplatelet therapy with clopidogrel [J].
Ishimatsu, Takashi ;
Sasaki, Ken-ichiro ;
Kakuma, Tatsuyuki ;
Harada, Atsushi ;
Hirakawa, Yuji ;
Fukumoto, Yoshihiro ;
Ueno, Takafumi .
JOURNAL OF CARDIOLOGY, 2020, 76 (05) :479-486
[28]   Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial [J].
Ohkubo, Kenji ;
Fujimoto, Yoshihide ;
Iwata, Yo ;
Kitahara, Hideki ;
Kadohira, Tadayuki ;
Sugimoto, Kazumasa ;
Morino, Tomoki ;
Kobayashi, Yoshio .
HEART AND VESSELS, 2014, 29 (01) :1-6
[29]   Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction [J].
Lee, Ji Hyun ;
Ahn, Sung Gyun ;
Lee, Jun-Won ;
Youn, Young Jin ;
Ahn, Min-Soo ;
Kim, Jang-Young ;
Yoo, Byung-Su ;
Lee, Seung-Hwan ;
Yoon, Junghan ;
Kim, Juwon ;
Choi, Eunhee ;
Yoo, Sang-Yong ;
Hung, Olivia Y. ;
Samady, Habib .
PLATELETS, 2016, 27 (04) :301-307
[30]   Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel [J].
Jang, Jae-Sik ;
Cho, Kyoung-Im ;
Jin, Han-Young ;
Seo, Jeong-Sook ;
Yang, Tae-Hyun ;
Kim, Dae-Kyeong ;
Kim, Dong-Soo ;
Seol, Sang-Hoon ;
Kim, Doo-Il ;
Kim, Bo-Hyun ;
Park, Yong Hyun ;
Je, Hyung-Gon ;
Jeong, Young-Hoon ;
Lee, Seung-Whan .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (04) :502-508